Rusfertide: The Hepcidin-Mimetic Peptide That Could End Routine Blood-Letting for Polycythemia Vera (July 4, 2026)
Table of Contents
The problem: too many red cells, and a very old treatment
Polycythemia vera (PV) is a slow-growing blood cancer - a myeloproliferative neoplasm, most often driven by a mutation in the JAK2 gene - in which the bone marrow makes far too many red blood cells. Thick, cell-crowded blood raises the risk of clots, strokes and heart attacks, so the central goal of treatment is to keep the hematocrit (the fraction of blood made up of red cells) below 45%. The mainstay for doing that is strikingly low-tech: therapeutic phlebotomy, the same blood-letting used for centuries. Draw off a unit of blood, and you remove red cells - but you also strip out iron, so the marrow, still revved up by the disease, simply rebuilds. Patients can end up on a treadmill of frequent blood draws, chronically iron-deficient, and worn down by fatigue, brain fog and restless legs. Rusfertide is built to break that cycle from a completely different angle: instead of removing red cells, it removes the marrow's raw material - iron.
What rusfertide is: a hormone, miniaturized
Iron in the body is governed by a single master hormone called hepcidin, a 25-amino-acid peptide made by the liver. Hepcidin works by latching onto ferroportin, the only protein that pumps iron out of cells, and forcing it to be pulled inside and destroyed. With ferroportin gone, iron gets locked inside gut cells, macrophages and liver cells, and less of it reaches the bloodstream. Rusfertide (formerly PTG-300, from Protagonist Therapeutics, now partnered with Takeda) is a synthetic 'mini-hepcidin' - an engineered peptide modeled on just the active front end of hepcidin (the first nine amino acids, DTHFPICIF), chemically reinforced so it resists being chewed up by enzymes and grips ferroportin tightly, at nanomolar potency. In effect, it is the iron hormone rebuilt as a practical, once-weekly, self-administered subcutaneous injection.
How it controls polycythemia vera
By mimicking hepcidin, rusfertide clamps down on ferroportin and restricts how much iron circulates. Starved of iron, the overactive marrow can't sustain its red-cell overproduction, so the hematocrit comes down and stays down - smoothly, rather than in the sawtooth pattern of draw-and-rebound that phlebotomy produces. Crucially, rusfertide redistributes iron rather than removing it from the body, which is why it can control the blood count while potentially easing the iron-deficiency symptoms that repeated phlebotomy inflicts. It doesn't replace disease-directed drugs like hydroxyurea or interferon; it targets the downstream plumbing of iron supply that all forms of PV depend on.
The Phase 3 VERIFY results
The pivotal test was the Phase 3 VERIFY trial (NCT05210790), which enrolled 293 phlebotomy-dependent PV patients and randomized them to add rusfertide or placebo to their standard of care. The results, reported in 2025, were decisive: 76.9% of patients on rusfertide achieved a clinical response - meaning hematocrit control without needing phlebotomy during weeks 20 to 32 - versus just 32.9% on standard of care alone (p<0.0001). The trial also met all four of its key secondary endpoints, including sustained hematocrit control and statistically significant improvements in patient-reported fatigue (PROMIS Fatigue) and overall symptom burden (the MFSAF total symptom score). In plain terms: about three-quarters of treated patients got off the phlebotomy treadmill, and they felt better doing it. These data built on the earlier Phase 2 REVIVE study and are being extended in the long-term THRIVE study (NCT06033586).
Safety and where it stands with the FDA
Across the program, rusfertide has been generally well tolerated. The most common side effects were injection-site reactions - redness, pain or swelling - and most were mild to moderate (grade 1/2), with no new safety signals and serious adverse events judged unrelated to the drug. (An earlier partial clinical hold in 2021, tied to a finding in rodents, was resolved and the program moved forward.) On the regulatory side, rusfertide already carried FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, and on March 2, 2026 the FDA accepted its New Drug Application and granted Priority Review, setting a decision date in the third quarter of 2026. If approved, it would be a first-in-class hepcidin-mimetic therapy for polycythemia vera.
Why it matters - and the honest caveats
Rusfertide is a flagship example of an emerging category: peptides that fine-tune iron biology. The same hepcidin-mimetic logic is being explored for other iron-overload conditions such as hereditary hemochromatosis and thalassemia, so a PV approval could open a broader door. That said, a few things are worth stating plainly. As of July 2026 rusfertide is investigational and not yet approved - a regulatory decision is still pending. Its evidence rests on trial endpoints like hematocrit control and phlebotomy avoidance over a defined window; long-term outcomes such as clot prevention and survival will keep accruing through extension studies. And, importantly, this is a prescription injectable studied under medical supervision - not a do-it-yourself research chemical. Any 'rusfertide' or 'PTG-300' powder sold online is illegitimate. It sits alongside other serious therapeutic peptides in hematology we cover, such as the stem-cell-mobilizer motixafortide and the complement inhibitor pegcetacoplan. This article is educational and not medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Takeda and Protagonist: FDA Accepts NDA and Grants Priority Review for Rusfertide (March 2026) Source
- [2] VERIFY: Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in polycythemia vera - ASCO 2025 Source
- [3] A Phase 3 Study of Rusfertide in Polycythemia Vera (VERIFY) - ClinicalTrials.gov NCT05210790 Source
- [4] Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera - The ASCO Post (2025) Source
Related Articles
Motixafortide (Aphexda): The FDA-Approved Peptide Working in Cancer Care — and Why Not Every Peptide Is About Weight Loss (June 17, 2026)
Most peptide headlines are about weight loss. Motixafortide (Aphexda, BL-8040) is a different kind of story: an FDA-approved cyclic peptide used in cancer care to mobilize stem cells for transplant — and now being tested against pancreatic cancer. Here's how it works and why it matters.
Pegcetacoplan: The Cyclic Peptide That Tamed Complement C3 - and Just Became the First Drug for Two Rare Kidney Diseases (July 3, 2026)
Pegcetacoplan started as compstatin, a lab peptide that grabs complement C3. Engineered into a PEGylated cyclic-peptide dimer, it's now approved for PNH, geographic atrophy, and - since July 2025 - as the first treatment for the rare kidney diseases C3G and IC-MPGN. Here's how a peptide reached the market three times over.